Cargando…
In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium
BACKGROUND: Praziquantel (PZQ) is the mainstay of schistosomiasis control and has been successfully used for decades. However, its mechanism of action is not fully understood. While the majority of studies have been conducted on Schistosoma mansoni, it is not known which enantiomer, R- or S-praziqua...
Autores principales: | Kovač, Jana, Vargas, Mireille, Keiser, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540299/ https://www.ncbi.nlm.nih.gov/pubmed/28764732 http://dx.doi.org/10.1186/s13071-017-2293-3 |
Ejemplares similares
-
Praziquantel, Mefloquine-Praziquantel, and Mefloquine-Artesunate-Praziquantel against Schistosoma haematobium: A Randomized, Exploratory, Open-Label Trial
por: Keiser, Jennifer, et al.
Publicado: (2014) -
Pharmacokinetic Study of Praziquantel Enantiomers and Its Main Metabolite R-trans-4-OH-PZQ in Plasma, Blood and Dried Blood Spots in Opisthorchis viverrini-Infected Patients
por: Meister, Isabel, et al.
Publicado: (2016) -
Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial
por: Barda, Beatrice, et al.
Publicado: (2016) -
Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.
por: King, C H, et al.
Publicado: (2000) -
Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.
por: Coles, G C, et al.
Publicado: (2001)